CAR-T Cells
DOI:
https://doi.org/10.61173/tx9d9p92Keywords:
CAR-T, Chimeric antigen receptor T cell, Cancer; ImmunotherapyAbstract
CAR-T (Chimeric antigen receptor T) cell therapy is an immunotherapy especially effective in treating hematological tumors. It has become a relatively good method for treating cancer
References
[1] L.A. Emens, et al., Eur. J. Cancer 81 (2017) 116–129.
[2] Y. Kuwana, et al., Biochem. Biophys. Res. Commun. 149 (3) (1987) 960–968.
[3] S. Feins, et al., Am. J. Hematol. 94 (S1) (2019) S3–S9.
[4] G. Gross, T. Waks, Z. Eshhar, Proc. Natl. Acad. Sci. USA 86 (24) (1989) 10024–10028.
[5] J. Styczynski, Acta Haematol. Pol. 51 (1) (2020) 2–5.
[6] C.A. Ramos, G. Dotti, Expert Opin. Biol. Ther. 11 (7) (2011) 855–873.
[7] J.S. Huston, et al., Proc. Natl. Acad. Sci. USA 85 (16) (1988) 5879–5883.
[8] R.E. Bird, et al., Science 242 (4877) (1988) 423–426.
[9] C. Zhang, et al., Biomark. Res. 5 (2017), 22-22.
[10] E.A. Reits, et al., J. Exp. Med. 203 (5) (2006) 1259–1271.
[11] N. Tokarew, et al., Br. J. Cancer 120 (1) (2019) 26–37.
[12] A.Z. Mehrabadi et al., Biomedicine & Pharmacotherapy 146 (2022) 112512
[13] Y. He, W. Zhang, Q. Xiao, et al., Asian J. Pharm. Sci. 17 (2022) 817–837.
[14] K.T. Magar, G.F. Boafo, X. Li, et al., Chin. Chem. Lett. 33 (2021) 587–596.
[15] Y. Xie, X. Li, J. Wu et al., Chin. Chem. Lett. 34 (2023) 108202.
[16] J.C. Fitzgerald, et al., Crit. Care Med. 45 (2) (2017) e124– e131 p.
[17] K.A. Hay, et al., Blood 130 (21) (2017) 2295–2306 p.
[18] X. Wang, et al., Blood 127 (24) (2016) 2980–2990 p.
[19] D.W. Lee, et al., Blood 124 (2) (2014) 188–195 p.
[20] S.C. Howard, D.P. Jones, C.H. Pui, N. Engl. J. Med. 364 (19) (2011) 1844–1854 p.
[21] S.A. Grupp, et al., N. Engl. J. Med. 368 (16) (2013) 1509– 1518 p.
[22] N. Tokarew, et al., Br. J. Cancer 120 (1) (2019) 26–37.
[23] O. ¨ Umut, et al., magazine of European, Med. Oncol. 14 (2) (2021) 143–149.
[24] E. Zah, et al., Cancer Immunol. Res. 4 (6) (2016) 498–508.
[25] M. Hegde, et al., J. Clin. Investig. 126 (8) (2016) 3036– 3052.
[26] M.L. Davila, et al., Sci. Trans. Med. 6 (224) (2014) 224ra25.
[27] J.N. Kochenderfer, et al., Blood 119 (12) (2012) 2709– 2720.
[28] S. Kailayangiri, et al., Cancers 12 (5) (2020) 1075.
[29] H. Salmon et al., J. Clin. Investig. 122 (3) (2012) 899–910.
[30] M.C. Poznansky, et al., J. Clin. Investig. 109 (8) (2002) 1101–1110.
[31] S. Spranger, et al., Cancer Cell 31 (5) (2017) 711–723.
[32] R.C. Sterner, R.M. Sterner, Blood Cancer J. 11 (4) (2021) 69.
[33] Y. Yin et al., Mol. Ther. Oncol. 11 (2018) 20–38.
[34] Chong, E.A., et al., Blood, the Journal Of the American Society of Hematology, 2017. 129(8):
[35] X. Li, W. Chen, Curr. Opin. Hematol. 26 (6) (2019) 427– 433.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
